GOTHENBURG, Sweden, July 22 /PRNewswire/ -- Cellectricon, a leading provider of cell-based screening solutions for research and drug discovery, today announced its collaboration with University of Lodz, Poland. Under the agreement University of Lodz invests in Cellaxess(R)HT, the world's first system for high throughput transfection enabling reagent-free delivery of any genetic material to cells.
To view the Multimedia News Release, please click:
"We are excited about the collaboration with Cellectricon and believe the Cellaxess(R)HT system will greatly advance our efforts in our research program focusing on cell biology and molecular genetics of clinically relevant genes related to cancer treatment," says Prof. Grzegorz Bartosz, head of Department of Molecular Biophysics at the University of Lodz. "Genomic screening is a rapidly-evolving field and the need is very significant for a technology enabling high transfection efficiency and viability in biologically relevant cell types. Cellaxess(R)HT will allow us to undertake ambitious expression and silencing screening projects that would have been both economically and practically unfeasible with conventional instrumentation." Purchase of the Cellaxess(R)HT system by the University of Lodz was made possible by funding from the Innovative Economy Operational Programme of the Republic of Poland, supported in part by the European Union through the European Regional Development Fund.
"Adoption of Cellaxess(R)HT by the University of Lodz into their research
program demonstrates the capabilities of this state-of-the-art system
designed for genomic research and screening. Cellectricon has developed the
system in close collaboration with leading research groups and leading
pharmaceutical companies to meet the inc
|SOURCE Cellectricon AB|
Copyright©2009 PR Newswire.
All rights reserved